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  According to Dirksen et al. (2013), the MH response spurs a 
cascade of reactions, including increased sympathetic 
activity, increased production of carbon dioxide, heat from 
rapid use of adenosine triphosphate (ATP), increased 
oxygen consumption, excess lactate production, and 
cellular damage and destruction. The cellular membrane 
disruption that occurs with MH has multiple consequences, 
including potassium, phosphate, magnesium, and 
myoglobin leakage into the extracellular fluid, causing a rise 
in serum levels (Klingler et al., 2014). Complications related 
to the progression of these cellular alterations include: 
skeletal muscle damage, hyperthermia, renal failure, 
cardiac arrest, and possible death (Dirksen et al., 2013).  
   MH is a rare, but life-threatening complication. Many 
clinicians may find themselves unprepared to manage a 
patient in a MH crisis. Hospitals should encourage their 
anesthesia providers to take part in routine clinical 
simulations to be better prepared to react promptly and 
efficiently. The research surrounding MH is ongoing, and 
complicated due to the rarity of these events. The 
cessation of previously known triggering agents, such as 
halothane, has substantially decreased the incidence of 
MH in the last 20 years (Heytens, Forget, Scholtes, & 
Veyckemans, 2015, p. 508). However, the need for 
research and development of treatment plans for this 
complication is vital to the continued decline in MH crisis 
events.  
  The pathophysiologic process initiated by these pharmacologic 
insults is characterized by a disruption in the regulation of calcium 
within muscle cells. This buildup of intracellular calcium results in 
the initiation of an immense hypermetabolic reaction stimulating 
widespread muscle contraction (McCance & Heuther, 2014, p. 
501). This buildup of intracellular calcium is a result of 
“uncontrolled sarcoplasmic calcium release caused by mutations 
in the ryanodine receptor subtype 1 (RYR1)” (Schuster, 
Johannsen, Schneiderbanger, & Roewer, 2013). This gene 
encodes an ion channel in the skeletal muscle cell through which 
calcium flows. “In the presence of an abnormal RYR1 gene in 
MH-susceptible individuals, a triggering agent such as halothane, 
isoflurane, sevoflurane, desflurane, or enflurane, either alone or 
in combination with the depolarizing muscle relaxant 
succinylcholine, initiates uncontrolled calcium release. This sets 
off the classic actin-myosin troponin interaction, shortening of 
muscle fibers, and consequent muscle contraction. The 
uncontrolled rise in intracellular calcium causes a sustained state 
of muscle contraction, leading to the hypermetabolic MH 
response” (Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt, 
2013, p. 331).  
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Introduction 
Complications related to the anesthetic process are 
multifaceted and abundant. As a future nurse anesthesia 
student, the underlying pathophysiology, diagnosis, and 
treatment of anesthesia-related complications are of particular 
interest.  One such anesthesia-induced life-threatening 
metabolic process involves the hypermetabolism of skeletal 
muscle. This pharmacogenetic process, known as malignant 
hyperthermia (MH), has a variable incidence rate ranging from 
1:10,000 to 1: 250,000 anesthetic cases. However, the 
prevalence of the genetic abnormalities may be as great as one 
in 400 individuals (Rosenberg, Pollock, Schiemann, Bulger, & 
Stowell, 2015, p. 1). “Malignant hyperthermia (MH) is a rare, 
but life-threatening, autosomal-dominant inherited disorder that 
may lead to metabolic crisis of skeletal muscle in susceptible 
individuals following exposure to triggering agents, such as 
volatile anesthetics or depolarizing muscle 
relaxants” (Schneiderbanger, Johannsen, Roewer, & Schuster, 
2014, p. 355).  
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Signs & Symptoms 
  “Almost all patients who are MH susceptible have no phenotypic 
changes without anesthesia, it is impossible to diagnose susceptibility 
without either exposure to the “trigger” anesthetics or by specific 
diagnostic testing” (Rosenberg et al., 2015, p. 2). This reinforces the 
importance of educating anesthesia providers, and nurses alike on 
the signs and symptoms of this pharmacogenetic process. 
“Characteristic clinical signs of MH during general anesthesia include 
hypoxemia, hypercapnia, tachycardia, muscular rigidity, acidosis, 
hyperkalemia and hyperthermia” (Schuster et al., 2013, p. 1). The 
“malignant hyperthermia clinical grading scale” bases the level of 
severity of MH crisis on six indicators: rigidity, muscle breakdown, 
respiratory acidosis, temperature increase, cardiac involvement, and 
other indicators of metabolic derangement not part of a single 
process (Heytens, Forget, Scholtes, & Veyckemans, 2015, p. 506). 
“An increase in end-tidal carbon dioxide despite increased minute 
ventilation provides an early diagnostic clue” (Rosenberg et al., 2015, 
p. 1).  
Implications for Nursing Care 
  “Many clinicians are unprepared to manage an MH crisis in 
the perioperative setting because it requires the use of low-
frequency, high-risk skills and procedures” (Cain, Riess, 
Gettrust, & Novalija, 2014, p. 301). Nurses should 
familiarize themselves with the signs and symptoms of MH, 
and be ready to implement their institutions treatment plan 
in the event of this complication. The widely accepted 
treatment for MH is to first remove the triggering anesthetic 
agent when an impeding MH crisis is expected (Cain et al., 
2014, p. 302). Dantrolene is a commonly used medication 
in the treatment of MH, which directly interferes with 
skeletal muscle contractions by decreasing the level of 
calcium in the muscle cells. Dantrolene does not block 
neuromuscular transmission, but rather potentiates 
nondepolarizing neuromuscular blockade (Brandom, & 
Riazi, 2015, p. 17). Active cooling in patients suffering from 
a MH crisis is paramount, with ice being the most widely 
used surface coolant. The patient’s core temperature 
should be lower than 39 degrees Celsius (Cain et al., 2014, 
p. 302).  
